|
Status |
Public on Aug 28, 2007 |
Title |
H1819 Control group treatment |
Sample type |
RNA |
|
|
Source name |
NSCLC cell line
|
Organism |
Homo sapiens |
Characteristics |
See publication for details
|
Treatment protocol |
Control treatment group. DMSO qod for 6 days.
|
Growth protocol |
See publication for details.
|
Extracted molecule |
total RNA |
Extraction protocol |
Trizol
|
Label |
biotin
|
Label protocol |
Affymetrix
|
|
|
Hybridization protocol |
please see the Southwestern Medical Center Microarray Core Facility website for details
|
Scan protocol |
please see the Southwestern Medical Center Microarray Core Facility website for details
|
Description |
H1819 Control treatment group. DMSO qod for 6 days.
|
Data processing |
Raw signal data without normalization
|
|
|
Submission date |
Jan 09, 2007 |
Last update date |
Aug 28, 2018 |
Contact name |
David S Shames |
E-mail(s) |
shames.david@gene.com
|
Phone |
650-225-7559
|
Organization name |
Genentech Inc
|
Department |
Oncology Biomarker Development
|
Lab |
Shames
|
Street address |
1 DNA Way
|
City |
South San Francisco |
State/province |
CA |
ZIP/Postal code |
94080 |
Country |
USA |
|
|
Platform ID |
GPL570 |
Series (2) |
GSE5816 |
A Genome-wide Screen for Hypermethylated Genes in Lung Cancer |
GSE6695 |
Genome-wide screen for promoter methylation in NSCLC identifies novel methylation markers for multiple malignancies |
|
Relations |
Reanalyzed by |
GSE64985 |
Reanalyzed by |
GSE119087 |